Marianne Ewertz

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
    Marianne Ewertz
    Department of Oncology ME, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
    J Clin Oncol 30:3967-75. 2012
  2. ncbi Effect of obesity on prognosis after early-stage breast cancer
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, Sdr Blvd 29, DK 5000 Odense, Denmark
    J Clin Oncol 29:25-31. 2011
  3. ncbi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
  4. ncbi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
  5. ncbi Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
    Jørn Andersen
    Department of Oncology, Arhus University Hospital, Arhus Sygehus, Denmark
    Acta Oncol 47:718-24. 2008
  6. ncbi Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study
    Jeanne Debess
    Department of Oncology, Aalborg Hospital, Aarhus University, Aalborg, Denmark
    Breast Cancer Res Treat 121:91-100. 2010
  7. ncbi Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
    Bent Ejlertsen
    Department of Oncology, Bldg 5012 Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 43:877-84. 2007
  8. ncbi Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, University of Southern Denmark, Denmark
    Acta Oncol 47:682-90. 2008
  9. ncbi The incorporation of marine n-3 PUFA into platelets and adipose tissue in pre- and postmenopausal women: a randomised, double-blind, placebo-controlled trial
    Petra M Witt
    Department of Oncology, Aalborg Hospital, Aarhus University Hospital, Hobrovej 18 22, Aalborg, Denmark
    Br J Nutr 104:318-25. 2010
  10. ncbi Comorbidity and survival after early breast cancer. A review
    Lotte Holm Land
    Department of Oncology, Odense University Hospital, Denmark
    Crit Rev Oncol Hematol 81:196-205. 2012

Collaborators

Detail Information

Publications20

  1. ncbi Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
    Marianne Ewertz
    Department of Oncology ME, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
    J Clin Oncol 30:3967-75. 2012
    ..7 years of median follow-up...
  2. ncbi Effect of obesity on prognosis after early-stage breast cancer
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, Sdr Blvd 29, DK 5000 Odense, Denmark
    J Clin Oncol 29:25-31. 2011
    ..This study was performed to characterize the impact of obesity on the risk of breast cancer recurrence and death as a result of breast cancer or other causes in relation to adjuvant treatment...
  3. ncbi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
    ..A cohort of premenopausal patients with primary hormone receptor positive breast cancer was prospectively identified to be eligible for the DBCG 89B trial. We perform a long-term follow-up and evaluate the external validity of the trial...
  4. ncbi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
    ..CONCLUSION: The results from the trial do not support a beneficial effect of oral pamidronate on the occurrence of bone metastases or fractures in patients with primary breast cancer receiving adjuvant chemotherapy...
  5. ncbi Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
    Jørn Andersen
    Department of Oncology, Arhus University Hospital, Arhus Sygehus, Denmark
    Acta Oncol 47:718-24. 2008
    ..A multivariate analysis in the per-protocol treated patients did not show significant differences in hazard ratios for DFS or OS among the three arms. Side-effects were rare but more common in the TAM2 and TAM/MA arms...
  6. ncbi Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study
    Jeanne Debess
    Department of Oncology, Aalborg Hospital, Aarhus University, Aalborg, Denmark
    Breast Cancer Res Treat 121:91-100. 2010
    ..Our results do not support that adjuvant chemotherapy is associated with cognitive side effects in breast cancer patients...
  7. ncbi Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
    Bent Ejlertsen
    Department of Oncology, Bldg 5012 Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 43:877-84. 2007
    ..The risk of secondary leukaemia and congestive heart failure was similar in the two groups. Overall CEF was superior over CMF in terms of DFS and OS in patients with operable breast cancer without subsequent increase in late toxicities...
  8. ncbi Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, University of Southern Denmark, Denmark
    Acta Oncol 47:682-90. 2008
    ..This formed the basis for recommending breast conserving surgery combined with radiotherapy as a standard treatment for suited breast cancer patients in Denmark...
  9. ncbi The incorporation of marine n-3 PUFA into platelets and adipose tissue in pre- and postmenopausal women: a randomised, double-blind, placebo-controlled trial
    Petra M Witt
    Department of Oncology, Aalborg Hospital, Aarhus University Hospital, Hobrovej 18 22, Aalborg, Denmark
    Br J Nutr 104:318-25. 2010
    ..However, supplementation with fish oil increased oestrogen levels in premenopausal women...
  10. ncbi Comorbidity and survival after early breast cancer. A review
    Lotte Holm Land
    Department of Oncology, Odense University Hospital, Denmark
    Crit Rev Oncol Hematol 81:196-205. 2012
    ..Survival after breast cancer is determined by disease related factors such as stage at diagnosis, patient characteristics, e.g., age, and treatment...
  11. ncbi Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008
    Lotte Holm Land
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000, Odense C, Denmark
    Breast Cancer Res Treat 131:1013-20. 2012
    ..While survival improved over time for patients without comorbidity, no improvement was seen among patients with severe comorbidity (CCI 3+)...
  12. ncbi ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer
    Jeanette Dupont Jensen
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000 Odense, Denmark
    Breast Cancer Res Treat 132:511-21. 2012
    ..Expression of ER, HER2, and TOP2A displayed discordance with a sufficient frequency to emphasize the role of confirmatory biopsies from metastatic lesions in future management of recurrent breast cancer...
  13. ncbi Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark
    Jeanne Debess
    Department of Oncology, Aalborg Hospital, Aarhus University, Denmark
    Acta Oncol 48:532-40. 2009
    ..The aim of this study was to assess cognitive function, quality of life, and psychological distress after surgery for early breast cancer but before initiation of adjuvant treatment...
  14. ncbi Marine n-3 polyunsaturated fatty acids in adipose tissue and breast cancer risk: a case-cohort study from Denmark
    Petra M Witt
    Department of Oncology, Aalborg Hospital, Aarhus University Hospital, Hobrovej 18 22, 9100, Aalborg, Denmark
    Cancer Causes Control 20:1715-21. 2009
    ....
  15. ncbi Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
    Bent Ejlertsen
    Department of Oncology, Bldg 5012 Rigshospitalet, Copenhagen University Hospital, DK 2100 Copenhagen, Denmark
    J Clin Oncol 24:4956-62. 2006
    ..To compare the efficacy of ovarian ablation versus chemotherapy in early breast cancer patients with hormone receptor-positive disease...
  16. ncbi Half body irradiation of patients with multiple bone metastases: a phase II trial
    Randi S Berg
    Department of Oncology, Aalborg Hospital, Aarhus University, Denmark
    Acta Oncol 48:556-61. 2009
    ..The primary aim of this study was to evaluate the effect of half-body irradiation (HBI) on pain and quality of life in cancer patients with multiple bone metastases. The secondary aim was to evaluate side effects of the treatment...
  17. ncbi Utility of 18FDG-PET/CT in breast cancer diagnostics--a systematic review
    Karina Warning
    Department of Oncology, Odense University Hospital, 5000 Odense, Denmark
    Dan Med Bull 58:A4289. 2011
    ..PET/CT should still be regarded as a supplement to conventional diagnostic procedures such as CT and MRI...
  18. ncbi PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer
    Jeanette Dupont Jensen
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Clin Cancer Res 17:667-77. 2011
    ..We wished to discern whether selective pressures occur and the influence of PIK3CA mutation on time to recurrence...
  19. ncbi Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group
    Mette S Thomsen
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Acta Oncol 47:654-61. 2008
    ..The work was initiated in 2003 and the guidelines were approved by the DBCG Radiotherapy Committee in 2006. The first of January 2007 the 3D guidelines had been fully implemented in five of the seven radiotherapy centres...
  20. ncbi Late effects of breast cancer treatment and potentials for rehabilitation
    Marianne Ewertz
    Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Denmark
    Acta Oncol 50:187-93. 2011
    ..Breast cancer is the most frequent malignant disease among women world wide. Survival has been improving leading to an increasing number of breast cancer survivors, in the US estimated to about 2.6 million...